Article
Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.
PloS one - 1 Jan 2019
Seatla Kaelo K, Choga Wonderful T, Mogwele Mompati, Diphoko Thabo, Maruapula Dorcas, Mupfumi Lucy, Musonda Rosemary M, Rowley Christopher F, Avalos Ava, Kasvosve Ishmael, Moyo Sikhulile, Gaseitsiwe Simani
Abstract excerpt
BACKGROUND: Roll-out of Integrase Strand Transfer Inhibitors (INSTIs) such as dolutegravir for HIV combination antiretroviral therapy (cART) in sub-Saharan Africa necessitates the development of affordable HIV drug resistance (HIVDR) assays targeting the Integrase gene. We optimised and evaluated an in-house integrase HIV-1 drug resistance assay (IH-Int) and compared it to a commercially available assay, ViroSeq™...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
